Eliminating Pediatric AIDS: No baby should be born with HIV and every mother should have the opportunity to see her baby thrive. Johnson & Johnson is working with partners to end new HIV infections in children by 2015 and keep their mothers alive.
Mother-to-child transmission of HIV is preventable. Yet, every day nearly 900 babies acquire HIV from their mothers during pregnancy, childbirth or breastfeeding. A vital part of the solution lies in the availability, even where resources are limited, of effective, inexpensive and safe medical interventions that prevent HIV transmission to infants and protect the health of their mothers.
Johnson & Johnson envisions a world in which no baby is born with HIV and every mother has the opportunity to help her baby thrive. Prevention of maternal-to-child transmission of HIV is a cornerstone of our philanthropic commitment, begun more than a decade ago, to which we remain dedicated.
We have pursued a comprehensive strategy to reduce the burden of HIV and AIDS on women and their families. Since 2003 we have committed more than $20 million to effective partnerships, including our long collaborations with mothers2mothers (m2m) and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). With these partners we have strengthened community health systems, provided individual counseling to pregnant women and tackled HIV-related social stigma and its devastating consequences.
We remain committed to ending the unnecessary global health tragedy of HIV among mothers and their children. In 2011 we pledged our commitment to support the United Nations Global Plan Towards the Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive. To support the plan’s priorities and its goal to virtually eliminate pediatric AIDS by reducing new infections in children by 90 percent, Johnson & Johnson pledged an additional four-year, $15 million commitment.
We continue to develop new strategies to serve the hardest-to-reach, most vulnerable women and children. Working with diverse partners, we focus our efforts in four key areas:
Funding psychosocial support for expectant and new mothers living with HIV.
Supporting Ministries of Health (MOH) that want to achieve the goals of the UN Global Plan.
Promoting creative mobile health solutions to persistent health system problems.
Providing expertise and global leadership.
Today, around the world, 34.2 million people are estimated to be HIV positive and 3.4 million of them are children. That number can change. Johnson & Johnson is dedicated to preventing HIV transmission from mothers to their children, and we are inspired to continue this important work. We will continue to foster innovation, promote partnership and provide visionary leadership to reach the day that no baby is born with HIV and no mother dies of AIDS.
Eliminating Pediatric AIDS: No baby should be born with HIV and every mother should have the opportunity to see her baby thrive. Johnson & Johnson is working with partners to end new HIV infections in children by 2015 and keep their mothers alive.
Mother-to-child transmission of HIV is preventable. Yet, every day nearly 900 babies acquire HIV from their mothers during pregnancy, childbirth or breastfeeding. A vital part of the solution lies in the availability, even where resources are limited, of effective, inexpensive and safe medical interventions that prevent HIV transmission to infants and protect the health of their mothers.
Johnson & Johnson envisions a world in which no baby is born with HIV and every mother has the opportunity to help her baby thrive. Prevention of maternal-to-child transmission of HIV is a cornerstone of our philanthropic commitment, begun more than a decade ago, to which we remain dedicated.
We have pursued a comprehensive strategy to reduce the burden of HIV and AIDS on women and their families. Since 2003 we have committed more than $20 million to effective partnerships, including our long collaborations with mothers2mothers (m2m) and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). With these partners we have strengthened community health systems, provided individual counseling to pregnant women and tackled HIV-related social stigma and its devastating consequences.
We remain committed to ending the unnecessary global health tragedy of HIV among mothers and their children. In 2011 we pledged our commitment to support the United Nations Global Plan Towards the Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive. To support the plan’s priorities and its goal to virtually eliminate pediatric AIDS by reducing new infections in children by 90 percent, Johnson & Johnson pledged an additional four-year, $15 million commitment.
We continue to develop new strategies to serve the hardest-to-reach, most vulnerable women and children. Working with diverse partners, we focus our efforts in four key areas:
Funding psychosocial support for expectant and new mothers living with HIV.
Supporting Ministries of Health (MOH) that want to achieve the goals of the UN Global Plan.
Promoting creative mobile health solutions to persistent health system problems.
Providing expertise and global leadership.
Today, around the world, 34.2 million people are estimated to be HIV positive and 3.4 million of them are children. That number can change. Johnson & Johnson is dedicated to preventing HIV transmission from mothers to their children, and we are inspired to continue this important work. We will continue to foster innovation, promote partnership and provide visionary leadership to reach the day that no baby is born with HIV and no mother dies of AIDS.
